Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034
Figure 2:
(a) Schematic structure of ALN-VSP formulation: The siRNA lipid nanoparticle is composed of cationic or ionizable lipid with cholesterol and encapsulated with two different siRNAs to target KSP and VEGF genes. The nanoparticles are stabilized by surface binding of PEGylated lipids. (b) CT images demonstrated a complete response of ALN-VSP in an endometrial cancer patient with multiple liver metastatic tumors (black arrows). (c) Dynamic contrast-enhanced MRI (DCE-MRI) images from another patient with three metastatic pancreatic neuroendocrine tumors in the right lobe of the liver (white arrows). A significant change of tumor blood flow was observed during the treatment at 0.7 mg/kg (indicated in red). Figures adapted with permission from [11].
Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."